vs

Side-by-side financial comparison of EASTERN CO (EML) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $55.3M, roughly 1.5× EASTERN CO). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 1.0%, a 21.7% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -22.4%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $3.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -0.6%).

China Eastern Airlines is a major airline in China, headquartered in Changning, Shanghai. It is one of the three major airlines in the country, along with Air China and China Southern Airlines.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

EML vs FDMT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.5× larger
FDMT
$85.1M
$55.3M
EML
Growing faster (revenue YoY)
FDMT
FDMT
+8508922.4% gap
FDMT
8508900.0%
-22.4%
EML
Higher net margin
FDMT
FDMT
21.7% more per $
FDMT
22.8%
1.0%
EML
More free cash flow
FDMT
FDMT
$25.4M more FCF
FDMT
$28.5M
$3.1M
EML
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-0.6%
EML

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
EML
EML
FDMT
FDMT
Revenue
$55.3M
$85.1M
Net Profit
$578.9K
$19.4M
Gross Margin
22.3%
Operating Margin
3.1%
17.3%
Net Margin
1.0%
22.8%
Revenue YoY
-22.4%
8508900.0%
Net Profit YoY
103.8%
139.1%
EPS (diluted)
$0.10
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EML
EML
FDMT
FDMT
Q4 25
$85.1M
Q3 25
$55.3M
$90.0K
Q2 25
$70.2M
$15.0K
Q1 25
$63.3M
$14.0K
Q4 24
$64.3M
$1.0K
Q3 24
$71.3M
$3.0K
Q2 24
$72.6M
$5.0K
Q1 24
$64.6M
$28.0K
Net Profit
EML
EML
FDMT
FDMT
Q4 25
$19.4M
Q3 25
$578.9K
$-56.9M
Q2 25
$3.4M
$-54.7M
Q1 25
$1.9M
$-48.0M
Q4 24
$1.3M
Q3 24
$-15.3M
$-43.8M
Q2 24
$3.5M
$-35.0M
Q1 24
$1.9M
$-32.4M
Gross Margin
EML
EML
FDMT
FDMT
Q4 25
Q3 25
22.3%
Q2 25
23.3%
Q1 25
22.4%
Q4 24
23.6%
Q3 24
25.5%
Q2 24
25.4%
Q1 24
23.9%
Operating Margin
EML
EML
FDMT
FDMT
Q4 25
17.3%
Q3 25
3.1%
-67983.3%
Q2 25
4.5%
-396373.3%
Q1 25
5.1%
-383007.1%
Q4 24
6.1%
Q3 24
9.5%
-1704400.0%
Q2 24
8.3%
-849120.0%
Q1 24
5.3%
-136200.0%
Net Margin
EML
EML
FDMT
FDMT
Q4 25
22.8%
Q3 25
1.0%
-63195.6%
Q2 25
4.9%
-364386.7%
Q1 25
3.1%
-342657.1%
Q4 24
2.0%
Q3 24
-21.5%
-1461433.3%
Q2 24
4.8%
-699060.0%
Q1 24
3.0%
-115717.9%
EPS (diluted)
EML
EML
FDMT
FDMT
Q4 25
$0.43
Q3 25
$0.10
$-1.01
Q2 25
$0.56
$-0.98
Q1 25
$0.32
$-0.86
Q4 24
$0.22
Q3 24
$-2.46
$-0.79
Q2 24
$0.56
$-0.63
Q1 24
$0.31
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EML
EML
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$9.2M
$402.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.3M
$505.7M
Total Assets
$220.0M
$566.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EML
EML
FDMT
FDMT
Q4 25
$402.7M
Q3 25
$9.2M
$305.1M
Q2 25
$9.1M
$293.2M
Q1 25
$10.2M
$321.4M
Q4 24
$16.1M
$424.9M
Q3 24
$9.7M
$501.9M
Q2 24
$2.0M
$541.9M
Q1 24
$2.1M
$525.9M
Total Debt
EML
EML
FDMT
FDMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$42.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EML
EML
FDMT
FDMT
Q4 25
$505.7M
Q3 25
$124.3M
$369.0M
Q2 25
$124.4M
$420.9M
Q1 25
$121.0M
$469.7M
Q4 24
$120.7M
$510.6M
Q3 24
$119.2M
$552.9M
Q2 24
$136.5M
$588.3M
Q1 24
$134.5M
$600.6M
Total Assets
EML
EML
FDMT
FDMT
Q4 25
$566.7M
Q3 25
$220.0M
$424.0M
Q2 25
$229.4M
$473.6M
Q1 25
$232.3M
$515.7M
Q4 24
$235.3M
$560.4M
Q3 24
$244.2M
$604.0M
Q2 24
$255.9M
$620.1M
Q1 24
$253.9M
$629.9M
Debt / Equity
EML
EML
FDMT
FDMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.35×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EML
EML
FDMT
FDMT
Operating Cash FlowLast quarter
$3.1M
$28.6M
Free Cash FlowOCF − Capex
$3.1M
$28.5M
FCF MarginFCF / Revenue
5.5%
33.5%
Capex IntensityCapex / Revenue
0.1%
0.1%
Cash ConversionOCF / Net Profit
5.38×
1.47×
TTM Free Cash FlowTrailing 4 quarters
$12.3M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EML
EML
FDMT
FDMT
Q4 25
$28.6M
Q3 25
$3.1M
$-46.5M
Q2 25
$3.8M
$-43.4M
Q1 25
$-1.8M
$-47.8M
Q4 24
$11.0M
$-134.6M
Q3 24
$-2.9M
$-29.4M
Q2 24
$8.4M
$-30.2M
Q1 24
$2.8M
$-29.1M
Free Cash Flow
EML
EML
FDMT
FDMT
Q4 25
$28.5M
Q3 25
$3.1M
$-46.6M
Q2 25
$3.0M
$-43.4M
Q1 25
$-2.7M
$-48.4M
Q4 24
$9.0M
$-138.4M
Q3 24
$-7.7M
$-31.2M
Q2 24
$7.3M
$-30.6M
Q1 24
$1.1M
$-29.8M
FCF Margin
EML
EML
FDMT
FDMT
Q4 25
33.5%
Q3 25
5.5%
-51765.6%
Q2 25
4.3%
-289620.0%
Q1 25
-4.3%
-345635.7%
Q4 24
13.9%
-13837100.0%
Q3 24
-10.8%
-1038966.7%
Q2 24
10.1%
-611840.0%
Q1 24
1.7%
-106421.4%
Capex Intensity
EML
EML
FDMT
FDMT
Q4 25
0.1%
Q3 25
0.1%
101.1%
Q2 25
1.1%
440.0%
Q1 25
1.3%
4507.1%
Q4 24
3.2%
378600.0%
Q3 24
6.7%
59266.7%
Q2 24
1.5%
6980.0%
Q1 24
2.6%
2535.7%
Cash Conversion
EML
EML
FDMT
FDMT
Q4 25
1.47×
Q3 25
5.38×
Q2 25
1.09×
Q1 25
-0.95×
Q4 24
8.41×
Q3 24
Q2 24
2.40×
Q1 24
1.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons